ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Nonsteroidal antiinflammatory drugs (NSAIDs)"

  • Abstract Number: 0728 • ACR Convergence 2021

    Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study

    Philip Conaghan1, Xavier Chevalier2, Linda Mindeholm3, Ursula Schramm3, Jens Praestgaard3, Abdelkader Seroutou3, Ronenn Roubenoff3 and Matthias Schieker3, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Henri Mondor University Hospital and Paris University XII, UPEC, Créteil, France, Créteil, France, 3Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland

    Background/Purpose: Knee osteoarthritis (OA) is a common musculoskeletal disease associated with pain and functional impairment. There are few effective therapies, often limited by side-effects.1 This…
  • Abstract Number: 1326 • ACR Convergence 2020

    Malignancy Risk Among Patients with Ankylosing Spondylitis in the United States: A Population-Based National Study

    Sali Merjanah1, Mohamad Bittar2 and Marina Magrey3, 1Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, 2The University of Tennessee Health Science Center, Memphis, TN, 3Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Increased cancer risk has been reported with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), but the correlation is poorly studied in Ankylosing spondylitis…
  • Abstract Number: 1375 • ACR Convergence 2020

    Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life?

    Charlotte Baert1, Charlene Mouafo Toukam2, Tatiana Sokolova3, Maria S. Stoenoiu4, Patrick Durez5, Laurent Meric De Bellefon2 and Adrien Nzeusseu Toukap6, 1Rheumatology department, St-Luc university hospitals, Brussels, Belgium, 2Rheumatology department; St-Luc University Hospitals, Brussels, Belgium, 3Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 41Department of Rheumatology, Cliniques Universitaires Saint-Luc, 2Institut de recherche expérimentale et cliniques (IREC), Brussels, Belgium, 5Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, 61Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium

    Background/Purpose: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (AxSpA) patients have shown that remission in Ankylosing Spondylitis and nonradiographic AxSpA patients treated without biologics (BIOL)…
  • Abstract Number: 1635 • ACR Convergence 2020

    Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database

    Amy Kenneally1, Frédérique Bariguian2, Richard Petruschke1, Arlene Tave3, Jess Edison4, Nicholas M. Sicignano5 and Francis Barbone1, 1GSK Consumer Healthcare, Warren, NJ, 2GSK Consumer Healthcare S.A., Nyon, Switzerland, 3PharmaLex US Corporation, Fairfax, VA, 4Walter Reed National Military Medical Center, Bethesda, 5Health ResearchTx LLC., Prevose, PA

    Background/Purpose: Diclofenac sodium gel 1% (DSG), a topical non-steroidal anti-inflammatory drug (NSAID), is effective for the relief of osteoarthritis (OA) pain in the elbows, wrists,…
  • Abstract Number: 1646 • ACR Convergence 2020

    Use of Prescription Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Adults with Hip/Knee Osteoarthritis (OA) at Increased Risk for NSAID-related Adverse Events

    Jayeshkumar Patel1, Wenhui Wei2, Raveendhara Bannuru3, Ravi Iyer4, Nazneen Fatima Shaikh1, Traci LeMasters1, Chibuzo Iloabuchi1, Degang Wang2 and Usha Sambamoorthi1, 1West Virginia University School of Pharmacy, Morgantown, WV, 2Regeneron Pharmaceuticals, Tarrytown, NY, 3Tufts Medical Center, Boston, MA, 4Teva Pharmaceutical Industries, West Chester, PA

    Background/Purpose: NSAIDs are commonly used for OA pain, but the benefits of pain relief must be carefully weighed against the potential risk for gastrointestinal (GI),…
  • Abstract Number: 1852 • ACR Convergence 2020

    Intestinal Permeability in the Adjuvant Induced Arthritis Model: Preliminary Study and Impact of NSAIDs

    Sophie Hecquet1, Romain Bordy2, Clement Prati1, Daniel Wendling3, Céline Demougeot2 and Frank Verhoeven1, 1Rheumatology, University Teaching Hospital, Besançon, France, 2EA4267 Laboratory, Besançon, France, 3CHU Besançon, department of rheumatology, Besancon, France

    Background/Purpose: The gut is no longer considered as a simple element associated with spondyloarthritis but as a real actor of the disease. In patients with…
  • Abstract Number: 1873 • ACR Convergence 2020

    The Changing Profile of Ankylosing Spondylitis in the Biologic Era

    Lauren Ridley1, Michael Weisman2, Lianne Gensler3, Michael Ward4, Mark Hwang5, Amirali Tahanan6, MinJae Lee7, Mohammad Rahbar6, Mariko Ishimori8, Matthew Brown9 and John Reveille10, 1McGovern Medical School at UTHealth, Houston, TX, 2Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, 3University of California San Francisco, San Francisco, CA, 4National Institutes of Health, Bethesda, MD, 5McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 6McGovern Medical School at UTHealth, Houston, 7UT Southwestern, Dallas, 8Cedars-Sinai Medical Center, Los Angeles, CA, 9Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, 10Department of Internal Medicine, University of Texas, Houston, TX

    Background/Purpose: To compare disease characteristics, comorbidities, and medication utilization of 573 patients with ankylosing spondylitis (AS) with short (< 20 years) disease duration (from symptom…
  • Abstract Number: 2023 • ACR Convergence 2020

    Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension

    Atul Deodhar1, Désirée van der Heijde2, Joachim Sieper3, Filip Van den Bosch4, Walter Maksymowych5, Tae-Hwan Kim6, Mitsumasa Kishimoto7, Andrew Östör8, Bernard Combe9, Yunxia Sui10, Xin Wang10, Alvina D. Chu11 and In-Ho Song10, 1Oregon Health & Science University, Portland, OR, 2Leiden University Medical Center, Leiden, Netherlands, 3Charité Universitätsmedizin Berlin, Berlin, Germany, 4Ghent University Hospital, Ghent, Belgium, 5University of Alberta, Edmonton, AB, Canada, 6Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 7Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 8Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, 9University of Montpellier, Montpellier, France, 10AbbVie Inc., North Chicago, IL, 11AbbVie, North Chicago, IL

    Background/Purpose: Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, was efficacious and well tolerated vs placebo (PBO) during the first 14 weeks (wks) of the phase…
  • Abstract Number: 1097 • 2019 ACR/ARP Annual Meeting

    Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study

    Lingyi Li1, Na Lu 1, Jacek Kopec 2, John Esdaile 3, Hui Xie 4 and J. Antonio Avina-Zubieta 2, 1Arthritis Research Canada, Vancouver, BC, Canada, 2Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, 4Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada

    Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are prescribed for the management of pain among patients with rheumatic diseases including systemic lupus erythematosus (SLE). However,…
  • Abstract Number: 2195 • 2019 ACR/ARP Annual Meeting

    BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel

    Joel A. Block1, Bharat Patel 2 and Sandy Yacoub Garas 3, 1Rush University Medical Center, Chicago, IL, 2GlaxoSmithKline Consumer Healthcare, Weybridge, United Kingdom, 3GlaxoSmithKline Consumer Healthcare, Warren, NJ

    Background/Purpose: Clinical trials demonstrate that diclofenac sodium gel 1% (DSG 1%), a topical NSAID, provides significantly better pain relief than vehicle placebo for patients with…
  • Abstract Number: 2197 • 2019 ACR/ARP Annual Meeting

    Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%

    Marc C. Hochberg1, Bharat Patel 2, Sandy Yacoub Garas 3 and Roy Altman 4, 1University of Maryland School of Medicine, Baltimore, MD, 2GlaxoSmithKline Consumer Healthcare, Weybridge, United Kingdom, 3GlaxoSmithKline Consumer Healthcare, Warren, NJ, 4University of California, Los Angeles

    Background/Purpose: Topical agents are recommended for the initial treatment of patients with knee osteoarthritis (OA). Diclofenac sodium gel 1% (DSG 1%), a topical nonsteroidal anti-inflammatory…
  • Abstract Number: 2880 • 2019 ACR/ARP Annual Meeting

    Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial

    Xenofon Baraliakos1, Laura Coates 2, Laure Gossec 3, Slawomir Jeka 4, Antonio Mera 5, Barbara Schulz 6, Michael Rissler 6, Ayan Das Gupta 7, Chiara Perella 6 and Effie Pournara 8, 1Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 2University of Oxford, Oxford, United Kingdom, 3Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 4University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, 5Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Healthcare Pvt Ltd, Hyderabad, India, 8Novartis Pharma AG, Basel, Basel-Stadt, Switzerland

    Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited…
  • Abstract Number: 2891 • 2019 ACR/ARP Annual Meeting

    Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs

    James Sullivan1, Jeffrey Katz 2 and Elena Losina 3, 1Brigham and Women's Hospital, Boston, 2Brigham and Women's Hospital/Harvard Medical School, Boston, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Knee OA is a disabling condition affecting over 14 million adults in the US. NSAIDs provide only short-term pain relief, creating the need for…
  • Abstract Number: 2952 • 2018 ACR/ARHP Annual Meeting

    Major NSAID Toxicity: Derivation and Internal Validation of a Simple Clinical Risk Score

    Daniel Solomon1, Ming Shao2, Katherine E Wolski3, Steven E Nissen4, M. Elaine Husni5 and Nina Paynter6, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Cleveland Clinic Foundation, Cleveland, OH, 3Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 4Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH, 5Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, 6Medicine, Harvard University, Boston, MA

    Background/Purpose: NSAIDs and Coxibs represent one of the most commonly prescribed drugs by rheumatologists and are used regularly by >10 million Americans. While most patients…
  • Abstract Number: 895 • 2018 ACR/ARHP Annual Meeting

    Associations of Statin Usage with Disease Activity in Ankylosing Spondylitis

    Jonathan Dau1, Lianne S. Gensler2, MinJae Lee3, Michael Ward4, Matthew Brown5, Laura A. Diekman6, Mohammad H. Rahbar7, Mariko Ishimori8, Michael Weisman9 and John D. Reveille10, 1McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, 2University of California San Francisco, San Francisco, CA, 3Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, 4National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, 5Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, 6Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, 7Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, 8Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 9Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 10McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: Recent studies have shown possible anti-inflammatory effects and a survival benefit with statin usage in ankylosing spondylitis (AS). The purpose of this study was…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology